Piontek Klaus, Selaru Florin M
Division of Gastroenterology and Hepatology, School of Medicine, Johns Hopkins University, Baltimore, Maryland.
Semin Liver Dis. 2015 Feb;35(1):55-62. doi: 10.1055/s-0034-1397349. Epub 2015 Jan 29.
Ever since their discovery, microRNAs (miRNAs) have been the subject of intense investigation of their roles in cells and tissues, both normal and disease state. Although some of the precise mechanisms of biogenesis and actions of miRNAs remain debatable, the fact that miRNAs are dysregulated in diseases such as cancer is undisputed. For many miRNA species, computational databases predict often numerous targets; however, experimental verification in vitro and in vivo is still lacking. For some miRNAs, species-specific targets have been validated; nevertheless, the precise mechanisms those targets act in and whether they are the only truly important ones remain to be discovered. The authors take a closer look at the current status of the role of miRNAs in the diagnosis and biology of cholangiocarcinomas where the perhaps biggest impact in the short term comes from the use of biomarkers in the early diagnosis.
自发现以来,微小RNA(miRNA)一直是深入研究其在正常和疾病状态下细胞与组织中作用的对象。尽管miRNA生物合成和作用的一些精确机制仍存在争议,但miRNA在诸如癌症等疾病中表达失调这一事实是无可争议的。对于许多miRNA种类,计算数据库常常预测出众多靶点;然而,体外和体内的实验验证仍然缺乏。对于一些miRNA,物种特异性靶点已得到验证;尽管如此,这些靶点发挥作用的精确机制以及它们是否是唯一真正重要的靶点仍有待发现。作者更深入地探讨了miRNA在胆管癌诊断和生物学中的作用现状,短期内其最大影响可能来自于生物标志物在早期诊断中的应用。